Anticancer effects of isofraxidin against A549 human lung cancer cells via the EGFR signaling pathway

HAN ZHANG¹, QIAN-QIAN FENG², JIAN-HUA GONG and JING-PING MA

Breath Internal Medicine Department, The Second Clinical Medical College, Jingzhou Central Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and Yangtze University, Jingzhou, Hubei 434100, P.R. China

Received August 13, 2017; Accepted March 15, 2018

DOI: 10.3892/mmr.2018.8950

Abstract. Lung cancer is the leading cause of mortality due to tumor malignancy worldwide. In recent years, the treatment of lung cancer with chemotherapy has demonstrated notable resistance and insensitivity. Therefore, it is of great importance to investigate anti-lung cancer drugs with high efficiency and low toxicity. In the present study, the effects of isofraxidin on lung cancer cells and the associated mechanisms were investigated. The results revealed that, in vivo and in vitro, isofraxidin exhibited marked inhibitory effects on the A549 lung cancer cell line. The results of Cell Counting kit-8, Transwell migration and Matrigel invasion assays, and flow cytometry to determine apoptosis, revealed that isofraxidin significantly inhibited the proliferation, migration and invasion of A549 cells, and induced the cell apoptosis. Furthermore, western blot analysis demonstrated that isofraxidin treatment led to effects on the expression of apoptosis-associated proteins, including members of the Bcl-2 protein family, and invasion-associated proteins, including matrix metallopeptidase (MMP)-2 and MMP-9, which may occur via inhibition of the expression of phosphorylated (p)-epidermal growth factor receptor, p-AKT and p-extracellular signal-regulated kinase. This regulation of protein expression may contribute to the inhibition of proliferation, migration and invasion of A549 lung cancer cells by isofraxidin. In addition, despite the inhibitory effects on the A549 lung cancer cell line, the present study revealed that isofraxidin exhibited low toxicity towards BEAS-2B normal lung epithelial cells within a certain dose range (0-160 µM), indicating that isofraxidin may be employed for lung cancer treatment with hypotoxicity and fewer side effects. In conclusion, isofraxidin may be a novel candidate for anti-lung cancer chemotherapy.

Introduction

Lung cancer is the leading cause of tumor malignancy-associated mortality worldwide. The morbidity of lung cancer has continuously increased and the overall five-year-survival rate is ~15% (1), which poses a threat to public health.

Lung cancer, which is also termed lung carcinoma, may be divided into four major types: Small-cell lung carcinoma, adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The latter three types are recognized collectively as non-small cell lung cancer, which accounts for ~85% of all lung cancers (2,3). At present, surgical operation is the most preferred and primary treatment for lung cancer at an early stage, which can completely remove the non-metastatic lesions to improve the long-term survival rate of patients (4,5). However, the majority of lung cancers are detected at a late stage of tumor development, and in these cases the opportunity for surgery is lost and non-surgical treatments are relied upon, including chemotherapy, radiotherapy and targeted therapy. In recent years, non-surgical treatment of lung cancer has been associated with characteristics of chemotherapeutic toxicity, drug resistance and insensitivity (6,7). Therefore, the development of novel anti-lung cancer drugs with high efficiency and low toxicity is essential.

Natural plants are an important source of novel pharmaceutical ingredients, and certain plants possess natural anticancer agents. Screening and investigating novel compounds from plants is an important strategy by which novel anticancer drugs with high efficiency and low toxicity may be identified (8). Isofraxidin is a coumarin compound that primarily exists in plants such as Sarcandra glabra and Acanthopanax senticosus (9). Isofraxidin has been reported to exhibit antibacterial, antioxidant, antidepressant and anti-inflammatory properties (10-12). Recently, isofraxidin was demonstrated to exert antitumor effects on two human colorectal adenocarcinoma cell lines, as the proliferation of HT-29 and SW-480 cells was inhibited by exposure to isofraxidin (9). Metastasis is the major factor associated with
the recurrence and mortality of patients with lung cancer. Yamazaki and Tokiwa (13) indicated that isofraxidin may reduce the expression of matrix metalloproteinase 7 (MMP7) protein, thus inhibiting the invasive ability of liver cancer cells; however, to the best of our knowledge, the effects of isofraxidin on lung cancer and the associated mechanisms have not previously been reported. The present study investigated the effect of isofraxidin on the proliferation, apoptosis, migration and invasion of A549 lung cancer cells, as well as the underlying mechanisms, which provided theoretical and data support for the clinical application of isofraxidin in lung cancer.

Materials and methods

Reagents. Isofraxidin (Fig. 1A) was purchased from Shanghai Yuan Ye Biotechnology Co., Ltd. (Shanghai, China). Isofraxidin was dissolved in dimethyl sulfoxide (DMSO) as the stock solution, which was stored at 4°C. The working solution of isofraxidin was diluted with Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) prior to use (the final DMSO concentration was <0.5% in all cultures).

Cell lines and culture. A549 human lung cancer and BEAS-2B human normal lung epithelial cell lines were purchased from the Cell resource center of Shanghai Institute of life sciences, Chinese academy of sciences (Shanghai, China). Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) and 100 U/ml penicillin and streptomycin in a humidified atmosphere containing 5% CO₂ at 37°C. Cells were cultured to a confluency of 80% and were subsequently digested with 0.25% trypsin and seeded into new plates at the required density.

Cell counting kit-8 (CCK-8) assay. Cell proliferation was evaluated via a CCK-8 assay (Beyotime Institute of Biotechnology, Shanghai, China) staining was used to detect the apoptosis of A549 cells treated with isofraxidin. A total of 1.5x10⁴ A549 cells per well of 6-well plate were exposed to isofraxidin (0, 10, 20 and 40 µM) at 37°C for 48 h, followed by fixing with 4% formaldehyde for 20 min at room temperature. Cells were subsequently stained with Hoechst 33342 (10 µg/ml) at 25°C in the dark for 20 min and cell apoptosis was immediately evaluated with a fluorescent microscope (magnification, x100). Three fields of view were employed for analysis of apoptotic rate.

Migration and invasion assays. Transwell inserts (EMD Millipore, Billerica, MA, USA) were utilized for A549 cell migration and invasion assays. Cells were diluted with serum-free DMEM at the logarithmic growth phase and 5x10⁴ cells in 200 µl serum-free DMEM were added in each upper chamber. A total of 500 µl DMEM medium containing 20% FBS was added into the lower chambers. In the invasion assay, Matrigel was also added to the upper well according manufacturer's protocol. After 1 h at 37°C, isofraxidin was added to reach a concentration of 0, 2.5, 5 and 10 µM. The concentrations of isofraxidin in upper and lower wells were in parallel. Following incubation at 37°C for 48 h, the cells on the upper membrane were removed by cotton swab. The cells at the bottom of the membrane were fixed with 4% formaldehyde at 25°C for 20 min, stained with 10% crystal violet at 25°C for 10-15 min and photographed under a light microscope (magnification, x200). Three fields of view were analyzed per sample.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RT-qPCR was used to determine the transcript levels of the invasion-associated proteins MMP-2, MMP-9. A549 cells were exposed to isofraxidin (0, 10, 20 and 40 µM) for 48 h at 37°C and the total RNA of cells was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). RT of isolated RNA was conducted (PrimeScript™ RT reagent kit; cat. no. RR037A, Takara Biotechnology Co., Ltd., Beijing, China) and amplified using the qPCR [ABI 7900HT Fast Real-Time PCR, (Applied Biosystems; Thermo Fisher Scientific, Inc.); SYBR-Green qPCR Master mix, cat. no. 638320; Takara Biotechnology Co., Ltd., Beijing, China) staining was used to detect the apoptosis of A549 cells treated with isofraxidin. A total of 1.5x10⁴ A549 cells per well of 6-well plate were exposed to isofraxidin (0, 10, 20 and 40 µM) at 37°C for 48 h, followed by fixing with 4% formaldehyde for 20 min at room temperature. Cells were subsequently stained with Hoechst 33342 (10 µg/ml) at 25°C in the dark for 20 min and cell apoptosis was immediately evaluated with a fluorescent microscope (magnification, x100). Three fields of view were employed for analysis of apoptotic rate.

Western blot analysis. A549 cells were treated with isofraxidin (0, 10, 20 and 40 µM) for 48 h at 37°C and collected. Cells lysis was conducted on ice for 30 min using lysis buffer, which consisted of a proteinase inhibitor mix, phosphatase inhibitor,
phenylmethylsulfonyl fluoride and radioimmunoprecipitation assay buffer (1:1:1:100; Beyotime Institute of Biotechnology, Shanghai, China). The supernatant was collected following centrifugation, 10,000 x g, 30 min, 4°C, the loading buffer was added and the mixture was boiled for 5 min. The BCA method was used to determine the protein concentration and 10 μg protein was loaded per loading well. Samples were analyzed by 10% SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 10% skim milk solution at 25°C for 1 h and incubated overnight at 4°C with the following primary antibodies: Rabbit anti-epidermal growth factor receptor (EGFR) antibody (cat. no. 4267S), rabbit anti-phosphorylated (p)-EGFR (pY1068) antibody (cat. no. 7005S), mouse anti-AKT antibody (cat. no. 2920S), mouse anti-p-AKT (pS473) antibody (cat. no. 4060S), anti-MMP2 antibody (cat. no. 40994S), rabbit anti-phosphorylated (p)-EGFR (pY1068) antibody (cat. no. 4267S), rabbit anti-Bcl-2-associated X (Bax) antibody (cat. no. 2777S), mouse anti-AKT antibody (cat. no. 2920S), mouse anti-p-AKT (pS473) antibody (cat. no. 4060S), rabbit anti-extracellular signal-regulated kinase (ERK) antibody (cat. no. 4695S), rabbit anti-p-ERK (pT202/Y204) antibody (cat. no. 4370S), rabbit anti-Bcl-2-associated X (Bax) antibody (cat. no. 2777S), rabbit anti-Bcl-2 antibody (cat. no. 2777S), rabbit anti-MMP-2 antibody (cat. no. 13667T), rabbit anti-MMP2 antibody (cat. no. 40994S), rabbit anti-GAPDH antibody (HRP Conjugate; cat. no. 8884S), which were purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA). All primary antibodies were diluted in 1:1000 proportion. GAPDH was used as the loading control. Following washing with TBST buffer (with 0.1% Tween-20), the PVDF membranes were incubated with species-specific horseradish peroxidase-conjugated secondary antibodies anti-mouse IgG, horseradish peroxidase (HRP)-linked antibody; cat. no. 7076; anti-rabbit IgG, HRP-linked antibody; cat. no. 7074; Cell Signaling Technology, Inc., (Danvers, MA, USA), 1:5,000 dilution) at 25°C for 1 h. The membranes were visualized using Pierce™ ECL Plus Western Blotting Substrate (Thermo Fisher Scientific, Inc.). Image Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MD, USA) was used for densitometry.

**In vivo xenograft study.** All procedures involving animals were approved by the Ethics Committee of the Jingzhou Central Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Jingzhou, China). A total of 18 male BALB/c nude mice were purchased from the CAVENS Laboratory Animal Company (Changzhou, China; http://www.cavens.com.cn/). The average weight of the mice was ~18 g. They were maintained under specific pathogen-free conditions at 20-25°C (Humidity: 50-60%; 12-h light dark cycle). A549 cells in PBS at 4x10^5/150 μl per mouse were injected subcutaneously into the 4-week-old nude mice. The mice were returned to their cages for continuous feeding. Ad libitum food and water was available. The tumor formation was regularly analyzed. The visible subcutaneous tumor was inspected by the naked eye. The tumor-bearing mice were separated into three groups: Negative control group (n=6 mice), isofraxidin-treated group (5 mg/kg, n=6 mice) and cisplatin-treated (Shanghai Yuanyeshengwu, Shanghai, China) positive control group (5 mg/kg, n=6 mice). Drugs were delivered daily by intraperitoneal injection for 21 days. All mice were sacrificed following the treatment period and the body weights and tumor volumes were measured. The expression levels of p-EGFR, p-AKT and p-ERK were detected by immunohistochemical staining as described previously (14).

**Statistical analysis.** All the assays were repeated in triplicate, data were processed using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA) and the results are presented as the mean ± standard deviation. The quantitative experiments were analyzed using analysis of variance. Dunnett's test was used as a post-hoc test. Statistical graphs were produced using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Figure 1. Isofraxidin inhibits the proliferation of A549 human non-small cell lung cancer cells. (A) Chemical structure of isofraxidin. (B) Cell proliferation of A549 cells exposed to isofraxidin at different concentrations for 24, 48 and 72 h was detected with a CCK-8 kit. (C) Cell proliferation of A549 and BEAS-2B cells after 48 h treatment with isofraxidin at different concentrations was detected with a CCK-8 kit. (D) Representative flow cytometry graphs indicating cell cycle distribution of A549 cells following 48 h treatment with isofraxidin at different concentrations. (E) Percentage of A549 cells in each cell cycle stage after 48 h treatment with isofraxidin at different concentrations was calculated: 0 μM (G0/G1, 58.63±0.94%; G2/M, 13.97±0.74%; S, 27.38±1.14%), 20 μM (G0/G1, 57.08±0.24%; G2/M, 11.62±0.58%; S, 31.30±0.52%), 40 μM (G0/G1, 56.25±0.46%; G2/M, 9.85±0.72%; S, 33.90±1.15%), 60 μM (G0/G1, 49.32±1.87%; G2/M, 7.08±0.39%; S, 43.60±1.56%). *P<0.05 vs. 0 μM isofraxidin. CCK-8, Cell Counting kit-8.
Results

Isofraxidin inhibits the proliferation of the A549 cell line. To determine the effect of isofraxidin on the proliferation of A549 cells and the optimal dosage, the cells were treated with isofraxidin at concentrations of 0, 5, 10, 20, 40, 80 and 160 μM for 24, 48 and 72 h. The results revealed that isofraxidin exhibited a dose- and time-dependent inhibitory effect on the proliferation of A549 cells (Fig. 1B), with half-maximal inhibitory concentration (IC₅₀) values of 28.76±1.36, 42.7±4.05 and 75.16±3.42 μM following 72, 48 and 24 h of treatment, respectively. Furthermore, a lower rate of inhibition was observed in BEAS-2B normal lung epithelial cells following isofraxidin treatment compared with A549 cells (Fig. 1C), with an IC₅₀ value of 85.32±2.34 μM after 48 h of treatment, indicating that within a certain dosage range, isofraxidin exhibited a lower toxicity towards normal lung epithelial cells compared with cancerous cells. Additionally, alterations in the cell cycle were analyzed by flow cytometry, the results of which demonstrated that following treatment with isofraxidin for 48 h, the cell cycle of A549 cells was markedly altered, particularly at concentrations of 20 and 40 μM, compared with the control cells (Fig. 1D and E). The percentage of cells in S phase increased in a dose-dependent manner (Fig. 1D and E), indicating that isofraxidin inhibited the proliferation of A549 cells by arresting cells in S phase.

Isofraxidin induces apoptosis in A549 cells in a dose-dependent manner. Drug-induced apoptosis was microscopically observed by Hoechst 33342 staining. A549 cells exposed to isofraxidin (0, 10, 20 and 40 μM) for 48 h were fixed, stained and observed under a microscope. The results demonstrated that the nuclei of cells in the control group were uniformly stained and the fluorescence intensity was not as strong compared with cells treated with isofraxidin. Increased fluorescence intensity in isofraxidin-treated cells appeared to be dose-dependent (Fig. 2A). When treated with 40 μM isofraxidin, nuclear pyknosis and crescent-shaped nuclei were observed, indicating that isofraxidin may induce the apoptosis of A549 cells in a dose-dependent manner (Fig. 2A). To determine the expression of two apoptosis-associated proteins, Bcl-2 and Bax, western blot analysis was performed. The ill-defined band of lower molecular weight is assumed to be nonspecific. The results revealed that the expression of Bax was significantly upregulated, while the expression Bcl-2 was significantly downregulated, in response to isofraxidin treatment in a dose-dependent manner (Fig. 2B). This result further indicated that isofraxidin may induce the apoptosis of A549 cells.

Isofraxidin suppresses the migration and invasion of A549 cells. Metastasis is closely associated with the prognosis and recurrence of cancer (15,16). To confirm the effects of isofraxidin on cell motility, Transwell migration and invasion assays were conducted. A549 cells were treated with isofraxidin at relatively low concentrations (0, 2.5, 5 and 10 μM) for 48 h, low concentrations of isofraxidin have little inhibitory effect on cell proliferation, which may affect the cell migration and invasion. The results revealed that the increase of isofraxidin concentration led to a decreased number of migratory/invasive cells, indicating that the migration and invasion of A549 cells was significantly inhibited compared with the corresponding controls (Fig. 3A). Western blot and RT-qPCR analyses of the expression of two invasion-associated genes, MMP-2 and MMP-9, revealed that the expression levels of MMP-2 and MMP-9 were significantly reduced following treatment with isofraxidin compared with control cells (Fig. 3B and C), which further confirmed the inhibitory effects of isofraxidin on the invasion of A549 cells.

Isofraxidin inhibits A549 cell proliferation, migration and invasion by inhibiting EGFR phosphorylation. Phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK)/ERK signaling pathways are important in the proliferation, apoptosis, invasion and migration of tumor cells (17-19). The alterations in p-AKT and p-ERK expression levels in A549 cells following isofraxidin treatment were detected by western blotting. The results demonstrated that the expression levels of p-AKT and p-ERK following treatment with isofraxidin was significantly inhibited in a dose-dependent manner (Fig. 4A and B). PI3K/AKT and MAPK/ERK signaling pathways are primarily regulated by receptor tyrosine kinases (RTKs) and EGFR is the principal member of the RTKs. Western blot analysis revealed that following treatment with isofraxidin, the expression levels of p-EGFR were significantly downregulated (Fig. 4C). Therefore, isofraxidin may inhibit the PI3K/AKT and MAPK/ERK signaling pathways by reducing the levels p-EGFR to hinder the development of lung cancer cells.

Isofraxidin suppresses tumor growth in vivo. To determine whether isofraxidin has potential therapeutic value for the treatment of lung carcinoma, the effects of isofraxidin on A549 cells were investigated in vivo in the present study using a xenograft mouse model. The weights of tumor-bearing nude mice are presented in Fig. 5A. Compared with in the positive control group, isofraxidin treatment reduced the body weight of nude mice less, with body weights more similar to those in the negative control group, indicating the potentially low toxicity and side effects of isofraxidin. The volume of the xenografts of samples collected after 21 days of treatment via intraperitoneal injection are presented in Fig. 5B. Compared with in the negative control group, isofraxidin significantly reduced the volume of the xenografts. Furthermore, Immunohistochemical detection demonstrated that following treatment with isofraxidin, the expression levels of p-EGFR, p-AKT and p-ERK were significantly downregulated compared with in the control group (Fig. 5C), which was consistent with the aforementioned in vitro results of the current study. These data indicated that isofraxidin suppressed the growth of xenografts in mice.

Discussion

Natural compounds have frequently been used to treat cancers. At present, there are >3,000 anticancer drugs that are derived from plants, including vinblastine, vincristine, etoposide, paclitaxel and camptothecin (8). Isofraxidin is a
A coumarin compound that primarily exists in ceratin plants, including Sarcandra glabra and Acanthopanax senticosus (9). Antibacterial, antioxidant, antidepressant, anti-inflammatory and antitumor effects of isofraxidin have previously been reported (20). As one of the most common types of malignant tumor, lung cancer is associated with certain characteristics, including rapid development and high metastasis, which is associated with high mortality. To the best of our knowledge, the effect of isofraxidin on lung cancer has not previously been reported; however, the present study revealed for the first time that isofraxidin may inhibit the proliferation, migration and invasion of A549 cells, and induce cell apoptosis, by inhibiting the EGFR signaling pathway.

The proliferation, apoptosis, migration and invasion of tumor cells involves a series of signaling pathways, making it a complex process with particular mechanisms that require further investigation. Bcl-2 family proteins are the most important regulatory factors in the mitochondrial apoptosis pathway and are made up of two primary groups: Apoptosis-inducing (apoptotic) proteins, including Bax, Bcl-2 antagonist/killer 1 and peptidyl-tRNA hydrolase 2, and apoptosis-inhibiting (antiapoptotic) proteins, including...
It was previously reported that isofraxidin significantly reduced the expression of the anti-apoptotic protein Bcl-2 in colon cancer cells and increased the expression of the apoptotic proteins caspase-3, caspase-9 and Bax (9). Therefore, the present study detected the effect of isofraxidin on the expression of Bcl-2 protein family members. The results revealed that isofraxidin promoted the expression of Bax but reduced the expression of Bcl-2 in a dose-dependent manner, indicating that isofraxidin may induce the apoptosis of A549 cells.

Patients with cancer succumb to the disease primarily due to the recurrence of malignant tumors and metastasis, and the key process resulting in the invasion and metastasis of malignant tumors is the degradation of the extracellular matrix (ECM). MMPs are the major enzymes that degrade the components of the ECM (24-26). In the process of developing safe and effective anticancer drugs, analysis of the antimetastatic ability of the drug is particularly important; the inhibition of MMP activity is also regarded as one aim of cancer treatment. It has been demonstrated that isofraxidin may suppress the invasion of hepatocellular carcinoma by inhibiting the expression of MMPs (13). Therefore, the present study investigated the effect of isofraxidin on expression of the MMP family proteins and the results revealed that the expression levels of MMP-2 and MMP-9 were significantly reduced following treatment with isofraxidin. The results of the present study indicated that isofraxidin was able to suppress the migration and invasion of A549 cells, as confirmed by Transwell migration and invasion assays.
PI3K/AKT and MAPK/ERK signaling pathways are important in the proliferation, apoptosis, migration and invasion of tumor cells. Numerous studies have reported that AKT may affect cell proliferation and apoptosis by regulating the Bcl-2 family-associated proteins (27,28). The results of the present study revealed that isofraxidin reduced the expression of p-AKT in A549 cells; therefore, isofraxidin may affect the expression of the Bcl-2 protein family by inhibiting the AKT signaling pathway, leading to the subsequent inhibition of the proliferation of A549 cells and the induction of apoptosis. ERK has been reported to regulate the expression of MMP family-associated proteins, thus affecting cell migration and invasion (29,30). The present study also revealed that isofraxidin reduced the expression of p-ERK in A549 cells, indicating that isofraxidin may inhibit the expression of MMP-2 and MMP-9 proteins by inhibiting the ERK signaling pathway, subsequently inhibiting the migration and invasion of A549 cells. RTKs are glycoproteins that span the cell membrane and bind a growth factor within its surface, which controls the transduction of cellular signals (31). There are numerous members of the RTK family, including EGFR, fibroblast growth factor receptor, vascular endothelial growth factor receptor and platelet-derived growth factor receptor (32). EGFR is considered to be among the most important members of the RTK family and its importance has been demonstrated by the clinical application of EGFR-targeting drugs, including gefitinib and afatinib (33).

Based on the effect of isofraxidin on PI3K/AKT and MAPK/ERK signaling pathways in the present study, isofraxidin may affect the activity of EGFR in lung cancer cells. The results of the present study revealed that the phosphorylation level of EGFR in lung cancer cells was significantly inhibited following treatment with treatment isofraxidin.

In conclusion, the present study confirmed the inhibitory effect of isofraxidin on lung cancer development. The results indicated that isofraxidin may inhibit the development of lung cancer cells by inhibiting the phosphorylation of EGFR and inhibiting the PI3K/AKT and MAPK/ERK signaling pathways. Furthermore, BEAS-2B human normal lung epithelial cells exhibited low sensitivity to isofraxidin within a certain dose range, indicating the potentially low toxicity and side effects of isofraxidin in the treatment of lung cancer. These results indicate the potential of isofraxidin as a novel candidate for anti-lung cancer chemotherapy.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data and materials described in this manuscript are available from the correspondence author upon reasonable request.

Authors’ contributions

HZ and QQF performed the experiments. JHG and JPM analyzed the data and wrote the manuscript.

Ethics approval and consent to participate

All procedures involving animals were approved by the Ethics Committee of the Jingzhou Central Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Jingzhou, China).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


